Acinetobacter Infections – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Acinetobacter Infections – Pipeline Review, H2 2016’, provides an overview of the Acinetobacter Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acinetobacter Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acinetobacter Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Acinetobacter Infections

The report reviews pipeline therapeutics for Acinetobacter Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Acinetobacter Infections therapeutics and enlists all their major and minor projects

The report assesses Acinetobacter Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Acinetobacter Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Acinetobacter Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Acinetobacter Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Achaogen Inc.

Adenium Biotech ApS

Aridis Pharmaceuticals LLC

AstraZeneca Plc

AvidBiotics Corp.

Cellceutix Corporation

Emergent BioSolutions Inc.

Entasis Therapeutics Inc

Evaxion Biotech ApS

F. Hoffmann-La Roche Ltd.

FOB Synthesis, Inc.

Hsiri Therapeutics, LLC

LegoChem Biosciences, Inc

Melinta Therapeutics, Inc

MicuRx Pharmaceuticals, Inc.

Nosopharm SAS

Novabiotics Limited

Omnia Molecular Ltd.

Peptilogics, Inc.

Pfizer Inc.

Sarepta Therapeutics, Inc.

Sealife PHARMA GMBH

Shionogi & Co., Ltd.

Techulon, Inc.

Tetraphase Pharmaceuticals Inc.

Varinel, Inc.

Vaxdyn, S.L.

Xellia Pharmaceuticals ApS

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Acinetobacter Infections Overview 8

Therapeutics Development 9

Pipeline Products for Acinetobacter Infections - Overview 9

Pipeline Products for Acinetobacter Infections - Comparative Analysis 10

Acinetobacter Infections - Therapeutics under Development by Companies 11

Acinetobacter Infections - Therapeutics under Investigation by Universities/Institutes 13

Acinetobacter Infections - Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Acinetobacter Infections - Products under Development by Companies 17

Acinetobacter Infections - Products under Investigation by Universities/Institutes 20

Acinetobacter Infections - Companies Involved in Therapeutics Development 21

Achaogen Inc. 21

Adenium Biotech ApS 22

Aridis Pharmaceuticals LLC 23

AstraZeneca Plc 24

AvidBiotics Corp. 25

Cellceutix Corporation 26

Emergent BioSolutions Inc. 27

Entasis Therapeutics Inc 28

Evaxion Biotech ApS 29

F. Hoffmann-La Roche Ltd. 30

FOB Synthesis, Inc. 31

Hsiri Therapeutics, LLC 32

LegoChem Biosciences, Inc 33

Melinta Therapeutics, Inc 34

MicuRx Pharmaceuticals, Inc. 35

Nosopharm SAS 36

Novabiotics Limited 37

Omnia Molecular Ltd. 38

Peptilogics, Inc. 39

Pfizer Inc. 40

Sarepta Therapeutics, Inc. 41

Sealife PHARMA GMBH 42

Shionogi & Co., Ltd. 43

Techulon, Inc. 44

Tetraphase Pharmaceuticals Inc. 45

Varinel, Inc. 46

Vaxdyn, S.L. 47

Xellia Pharmaceuticals ApS 48

Acinetobacter Infections - Therapeutics Assessment 49

Assessment by Monotherapy Products 49

Assessment by Target 50

Assessment by Mechanism of Action 52

Assessment by Route of Administration 54

Assessment by Molecule Type 56

Drug Profiles 58

A-3APO - Drug Profile 58

AA-139 - Drug Profile 60

ACHN-975 Prodrug - Drug Profile 61

Acinetobacter vaccine - Drug Profile 62

Antisense Oligonucleotide for Acinetobacter baumannii Infections - Drug Profile 63

Antisense Oligonucleotide for Acinetobacter baumannii Infections - Drug Profile 64

AR-401 - Drug Profile 65

AvR2-V10 - Drug Profile 66

CA-824 - Drug Profile 68

ETX-2514 - Drug Profile 69

EV-035 - Drug Profile 70

Fab-001 - Drug Profile 72

FSI-1671 - Drug Profile 73

FSI-1686 - Drug Profile 74

GN-4474 - Drug Profile 75

HT-06 - Drug Profile 76

HT-07 - Drug Profile 77

HT-10 - Drug Profile 78

LCB-010200 - Drug Profile 79

LCB-100200 - Drug Profile 80

MDN-0057 - Drug Profile 81

Monoclonal Antibodies for Gram-Negative Bacterial Infections - Drug Profile 83

MRX-V - Drug Profile 84

NOSO-95179 - Drug Profile 85

NP-432 - Drug Profile 86

OM-011818 - Drug Profile 87

Peptides for Infectious Diseases - Drug Profile 88

PMX-100 - Drug Profile 89

PMX-1091 - Drug Profile 90

PMX-1142 - Drug Profile 91

PMX-229 - Drug Profile 92

PMX-633 - Drug Profile 93

pneumonia vaccine - Drug Profile 94

RX-05 - Drug Profile 95

RXP-873 - Drug Profile 96

S-649266 - Drug Profile 97

SLP-0901 - Drug Profile 99

SLP-0905 - Drug Profile 100

Small Molecule for Acinetobacter baumannii Infections - Drug Profile 101

Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Drug Profile 102

Small Molecule to Target Bacterial Cell Membrane for Acinetobacter Infections - Drug Profile 103

Small Molecules for Acinetobacter baumannii Infection - Drug Profile 104

Small Molecules for Acinetobacter Infections - Drug Profile 105

Small Molecules for Bacterial Infections - Drug Profile 106

Small Molecules for Bacterial Infections - Drug Profile 107

Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile 108

Small Molecules to Inhibit Aminoacyl-tRNA Synthetases for Bacterial Infections - Drug Profile 109

Small Molecules to Inhibit LpxC for Gram-Negative Bacterial Infections - Drug Profile 110

Small Molecules to Inhibit NDH-1 for Acinetobacter baumannii Infections - Drug Profile 111

SPR-741 - Drug Profile 112

Synthetic Peptide for Gram-Negative Bacterial Infections - Drug Profile 113

TP-6076 - Drug Profile 114

VAR-10100 - Drug Profile 115

VXD-001 - Drug Profile 116

VXD-003 - Drug Profile 117

XEL-1001 - Drug Profile 118

XEL-1002 - Drug Profile 119

XEL-1003 - Drug Profile 120

XEL-1007 - Drug Profile 121

Acinetobacter Infections - Dormant Projects 122

Acinetobacter Infections - Product Development Milestones 124

Featured News & Press Releases 124

Appendix 125

Methodology 125

Coverage 125

Secondary Research 125

Primary Research 125

Expert Panel Validation 125

Contact Us 125

Disclaimer 126

List of Tables

List of Tables

Number of Products under Development for Acinetobacter Infections, H2 2016 13

Number of Products under Development for Acinetobacter Infections – Comparative Analysis, H2 2016 14

Number of Products under Development by Companies, H2 2016 15

Number of Products under Development by Companies, H2 2016 (Contd..1) 16

Number of Products under Investigation by Universities/Institutes, H2 2016 17

Comparative Analysis by Late Stage Development, H2 2016 18

Comparative Analysis by Clinical Stage Development, H2 2016 19

Comparative Analysis by Early Stage Development, H2 2016 20

Products under Development by Companies, H2 2016 21

Products under Development by Companies, H2 2016 (Contd..1) 22

Products under Development by Companies, H2 2016 (Contd..2) 23

Products under Investigation by Universities/Institutes, H2 2016 24

Acinetobacter Infections – Pipeline by Achaogen Inc., H2 2016 25

Acinetobacter Infections – Pipeline by Adenium Biotech ApS, H2 2016 26

Acinetobacter Infections – Pipeline by Aridis Pharmaceuticals LLC, H2 2016 27

Acinetobacter Infections – Pipeline by AstraZeneca Plc, H2 2016 28

Acinetobacter Infections – Pipeline by AvidBiotics Corp., H2 2016 29

Acinetobacter Infections – Pipeline by Cellceutix Corporation, H2 2016 30

Acinetobacter Infections – Pipeline by Emergent BioSolutions Inc., H2 2016 31

Acinetobacter Infections – Pipeline by Entasis Therapeutics Inc, H2 2016 32

Acinetobacter Infections – Pipeline by Evaxion Biotech ApS, H2 2016 33

Acinetobacter Infections – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 34

Acinetobacter Infections – Pipeline by FOB Synthesis, Inc., H2 2016 35

Acinetobacter Infections – Pipeline by Hsiri Therapeutics, LLC, H2 2016 36

Acinetobacter Infections – Pipeline by LegoChem Biosciences, Inc, H2 2016 37

Acinetobacter Infections – Pipeline by Melinta Therapeutics, Inc, H2 2016 38

Acinetobacter Infections – Pipeline by MicuRx Pharmaceuticals, Inc., H2 2016 39

Acinetobacter Infections – Pipeline by Nosopharm SAS, H2 2016 40

Acinetobacter Infections – Pipeline by Novabiotics Limited, H2 2016 41

Acinetobacter Infections – Pipeline by Omnia Molecular Ltd., H2 2016 42

Acinetobacter Infections – Pipeline by Peptilogics, Inc., H2 2016 43

Acinetobacter Infections – Pipeline by Pfizer Inc., H2 2016 44

Acinetobacter Infections – Pipeline by Sarepta Therapeutics, Inc., H2 2016 45

Acinetobacter Infections – Pipeline by Sealife PHARMA GMBH, H2 2016 46

Acinetobacter Infections – Pipeline by Shionogi & Co., Ltd., H2 2016 47

Acinetobacter Infections – Pipeline by Techulon, Inc., H2 2016 48

Acinetobacter Infections – Pipeline by Tetraphase Pharmaceuticals Inc., H2 2016 49

Acinetobacter Infections – Pipeline by Varinel, Inc., H2 2016 50

Acinetobacter Infections – Pipeline by Vaxdyn, S.L., H2 2016 51

Acinetobacter Infections – Pipeline by Xellia Pharmaceuticals ApS, H2 2016 52

Assessment by Monotherapy Products, H2 2016 53

Number of Products by Stage and Target, H2 2016 55

Number of Products by Stage and Mechanism of Action, H2 2016 57

Number of Products by Stage and Route of Administration, H2 2016 59

Number of Products by Stage and Molecule Type, H2 2016 61

Acinetobacter Infections – Dormant Projects, H2 2016 126

Acinetobacter Infections – Dormant Projects (Contd..1), H2 2016 127

List of Figures

List of Figures

Number of Products under Development for Acinetobacter Infections, H2 2016 13

Number of Products under Development for Acinetobacter Infections – Comparative Analysis, H2 2016 14

Number of Products under Development by Companies, H2 2016 15

Number of Products under Investigation by Universities/Institutes, H2 2016 17

Comparative Analysis by Early Stage Products, H2 2016 20

Assessment by Monotherapy Products, H2 2016 53

Number of Products by Top 10 Targets, H2 2016 54

Number of Products by Stage and Top 10 Targets, H2 2016 54

Number of Products by Top 10 Mechanism of Actions, H2 2016 56

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 56

Number of Products by Routes of Administration, H2 2016 58

Number of Products by Stage and Routes of Administration, H2 2016 58

Number of Products by Molecule Types, H2 2016 60

Number of Products by Stage and Molecule Types, H2 2016 60

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports